Methotrexate hydrate (CAS 133073-73-1)

Methotrexate hydrate functions as an antimetabolite by inhibiting the enzyme dihydrofolate reductase, which is essential for the synthesis of purines and pyrimidines. By doing so, it disrupts the production of DNA and RNA, ultimately interfering with cellular proliferation. Methotrexate hydrate acts as an immunosuppressant by inhibiting the synthesis of tetrahydrofolic acid, which is necessary for the proliferation of T cells. Methotrexate hydrate exerts its influence on cellular processes by disrupting the folate pathway, leading to the accumulation of toxic metabolites and the inhibition of DNA synthesis. This disruption ultimately leads to the suppression of immune responses and the inhibition of cancer cell growth. Methotrexate hydrate induces apoptosis in cancer cells by interfering with the production of nucleotides, which are essential for DNA replication and repair. Methotrexate hydrate′s mechanism of action involves targeting key cellular processes, such as DNA and RNA synthesis, as well as immune cell proliferation, ultimately leading to its antimetabolic and immunosuppressive effects.